Entera Bio Ltd.
ENTX Nasdaq
SEC CIK 1638097
Follow Entera Bio Ltd.
Weekly email: filings, results, news
Revenue, last quarter
$0
Net income
−$7.3M
−175.3% vs same quarter last year
EPS, diluted
$0.14
+133.3% vs same quarter last year
Operating cash flow
−$3.5M
−112.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $42K | −$11.4M |
| FY24 | $181K | −$9.5M |
| FY23 | $0 | −$8.9M |
| FY22 | $134K | −$13.1M |
| FY21 | $571K | −$12.2M |
| FY20 | $365K | −$11.2M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 0% | −27450% | −27235.7% |
| FY24 | 5% | −5295.6% | −5271.3% |
| FY23 | - | - | - |
| FY22 | 24.6% | −9714.2% | −9754.5% |
| FY21 | 34.7% | −2139.6% | −2134.3% |
| FY20 | 17.8% | −3059.7% | −3072.9% |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$7.5M |
| FY24 | −$6.8M |
| FY23 | −$7.3M |
| FY22 | −$12.5M |
| FY21 | −$9.1M |
| FY20 | −$10.6M |
| FY19 | - |
- Entera Bio Ltd.
- Healthcare median
Show the numbers
| Year | Entera Bio Ltd. | Healthcare median |
|---|---|---|
| FY25 | −27235.7% | −40.6% |
| FY24 | −5271.3% | −60.7% |
| FY23 | - | −97.1% |
| FY22 | −9754.5% | −128.5% |
| FY21 | −2134.3% | −129.2% |
| FY20 | −3072.9% | −136.5% |
| FY19 | - | −133.7% |
News
No stories filed under Entera Bio Ltd. yet - coverage appears here as the news feed clusters it.